Zhejiang East Asia Pharmaceutical Co (605177) Fair Value & Analysis
Healthcare · CN · Market cap 2.4B CNY
Fair value as of: Jul 12, 2026
From 4 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥70.84 to ¥8.81 (−87.6%) since Jun 24, 2026. Share price −23.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥16.03 – ¥23.77 · fair‑value band ¥5.00 – ¥12.61 · the ¥16.39 price screens above the ¥8.81 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zhejiang East Asia Pharmaceutical Co (605177) currently trades at ¥16.39, while our model-based Fair Value estimate is ¥8.81 — implying the stock looks roughly 46.3% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Zhejiang East Asia Pharmaceutical Co generated revenue of 1.0B CNY at a net margin of -10.9%. Revenue grew 38.6% year over year. It earns a return on equity of -6.1%. Net debt stands at 737M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥5.00 (bear case) to ¥12.61 (bull case); at ¥16.39, the current price sits above that range. The share trades about 34% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -46%, 605177 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company provides products in the fields of cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms. It serves customers through a sales network in Japan, South Korea, Europe, America, Southeast Asia, and internationally. Zhejiang East Asia Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Taizhou, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang East Asia Pharmaceutical Co reported revenue of ¥940M in FY2025 versus ¥712M in FY2021, a compound +7.2%/yr. Reported net income was −¥82.4M in FY2025.
Is 605177 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang East Asia Pharmaceutical Co (605177) undervalued?
What is the fair value of 605177?
What is the quality score of 605177?
What is the revenue of Zhejiang East Asia Pharmaceutical Co (605177)?
What is the net profit margin of 605177?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Zhejiang East Asia Pharmaceutical Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.